The purpose of the study is to evaluate the presence of early vascular aging 6 months and12 months after COVID-19 infection.
After being informed about the study and potential risks, all eligible patients giving
written informed consent will undergo a comprehensive non-invasive assessment of vascular
and cardiac function 6 months and 12 months after COVID-19 infection. Cardiovascular
events and mortality will be collected 2, 5 and 10 years after inclusion
Diagnostic Test: carotid-femoral pulse-wave velocity
early vascular aging tests
Other Name: arterial distensibility,wave separation/intensity analysis,flow-mediated dilation,cardiac diastolic dysfunction,myocardial stiffness,central blood pressure
Inclusion Criteria:
- age >18 years, both sexes;
- written informed consent;
- affiliation to a social security regime;
- a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group
1,2,3)
- hospitalization in intensive care unit for COVID19 (for group 1)
- hospitalization in a medicine unit for COVID19 (for group 2)
- no hospitalization for COVID19 or hospitalization less than 24h (for group 3)
- a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4)
Exclusion Criteria:
- Age <18 years
- Inability to express consent of the study
- Diseases carrying out a life -expectancy <1 year according to clinical judgment
- Pregnancy and breastfeeding
- Foreseen inability to attend scheduled visits
CHRU Nancy
Nancy, France
Hôpital Européen Georges Pompidou - APHP
Paris, France
CHU Rouen
Rouen, France
Rosa Maria BRUNO, MD
+33 1 53 98 79 67
rosa-maria.bruno@inserm.fr
Laura LE MAO, MSc
+33 1 56 09 54 97
laura.le-mao@aphp.fr
Pierre BOUTOUYRIE, MD PHD, Principal Investigator
Assistance Publique - Hôpitaux de Paris